|
This article may be reprinted free of charge provided 1) that there is clear attribution to the Orthomolecular Medicine News Service, and 2) that both the OMNS free subscription link http://orthomolecular.org/subscribe.html and also the OMNS archive link http://orthomolecular.org/resources/omns/index.shtml are included. FOR IMMEDIATE RELEASE
Reigniting Hope: Managing Systemic Lupus Erythematosus with Integrative Orthomolecular Medicine
Richard Z. Cheng, M.D., Ph.D.OMNS (Nov 16, 2024) A recent story from Shanghai highlights the difficult journey of SLE patients. A woman named Shabai, after two decades battling this autoimmune disease and suffering kidney failure requiring dialysis, sought relief through assisted death in Switzerland. In her final social media post on October 24, 2024, she expressed gratitude for a 'wonderful life,' offering a heartfelt farewell with her father. Shabai's story has ignited public empathy, underscoring the profound impact of SLE on physical and emotional well-being. Having been asked to write about SLE, I aim to explore how integrative orthomolecular medicine can offer effective management strategies for this complex condition. Through a holistic approach that addresses root causes, nutrient support, and lifestyle factors, integrative orthomolecular medicine opens new avenues for reducing symptoms and enhancing quality of life. Patients with SLE should not give up hope; there are promising strategies that can empower them to live healthier, fuller lives despite their diagnosis. Introduction: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by the production of autoantibodies and immune complex formation, affecting multiple organ systems. While the exact etiology remains unclear, an integrative orthomolecular approach can provide insights into the root causes and intermediary mechanisms involved in SLE development and progression. Root Causes Contributing to SLE:
Intermediary Mechanisms in SLE
Integrative Intervention:
Summary of Key Benefits:
Conclusion: Addressing root causes and intermediary mechanisms in SLE through integrative methods offers promise for improved outcomes. By combining nutritional, environmental, and lifestyle modifications with targeted interventions for immune regulation and oxidative stress, SLE patients may experience relief and enhanced quality of life. Integrative orthomolecular medicine presents a holistic, patient-centered approach to nurturing resilience and optimism in the face of chronic autoimmune challenges. Through this integrative orthomolecular approach, we have observed significant improvements in our patients' quality of life (126,127). In many cases, these methods have even contributed to reversing symptoms of various autoimmune diseases. This experience reinforces the potential of integrative medicine to provide renewed hope and health to those facing the challenges of autoimmune conditions. References:1. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-de-la-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr Res Rev. 2017 Jun;30(1):118-37. 2. Castro-Webb N, Cozier YC, Barbhaiya M, Ruiz-Narváez EA, Li S, Costenbader KH, et al. Association of macronutrients and dietary patterns with risk of systemic lupus erythematosus in the Black Women's Health Study. Am J Clin Nutr. 2021 Oct 1;114(4):1486-94. 3. DiNicolantonio JJ, O'Keefe J. The Importance of Maintaining a Low Omega-6/Omega-3 Ratio for Reducing the Risk of Autoimmune Diseases, Asthma, and Allergies. Mo Med. 2021;118(5):453-9. 4. Simopoulos AP. Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases. J Am Coll Nutr. 2002 Dec 1;21(6):495-505. 5. Pestka JJ, Vines LL, Bates MA, He K, Langohr I. Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse. PloS One. 2014;9(6):e100255. 6. Liu A, Li Z, Zeng J, Peng Y, Wang S, Bi X, et al. ω-3 polyunsaturated fatty acid alleviates systemic lupus erythematosus by suppressing autoimmunity in a murine model. Int Immunopharmacol. 2024 Jan 5;126:111299. 7. Reifen R, Blank M, Afek A, Kopilowiz Y, Sklan D, Gershwin ME, et al. Dietary polyunsaturated fatty acids decrease anti-dsDNA and anti-cardiolipin antibodies production in idiotype induced mouse model of systemic lupus erythematosus. Lupus. 1998;7(3):192-7. 8. Fernandes G. Dietary lipids and risk of autoimmune disease. Clin Immunol Immunopathol. 1994 Aug;72(2):193-7. 9. Rossato S, Oakes EG, Barbhaiya M, Sparks JA, Malspeis S, Willett WC, et al. Ultraprocessed Food Intake and Risk of Systemic Lupus Erythematosus Among Women Observed in the Nurses' Health Study Cohorts. Arthritis Care Res. 2024 Jun 27; 10. Hamid R, Masood A. Dietary Lectins as Disease Causing Toxicants [Internet]. [cited 2024 Nov 3]. Available from: https://scialert.net/abstract/?doi=pjn.2009.293.303 11. Vojdani A. Lectins, agglutinins, and their roles in autoimmune reactivities. Altern Ther Health Med. 2015;21 Suppl 1:46-51. 12. Petroski W, Minich DM. Is There Such a Thing as "Anti-Nutrients"? A Narrative Review of Perceived Problematic Plant Compounds. Nutrients. 2020 Oct;12(10):2929. 13. Popova A, Mihaylova D. Antinutrients in Plant-based Foods: A Review. [cited 2024 Nov 3]; Available from: https://openbiotechnologyjournal.com/VOLUME/13/PAGE/68/ 14. Freed DLJ. Lectins in Food: Their Importance in Health and Disease. J Nutr Med. 1991 Jan 1;2(1):45-64. 15. Balkrishna A, Thakur P, Singh S, Chandra Dev SN, Varshney A. Mechanistic Paradigms of Natural Plant Metabolites as Remedial Candidates for Systemic Lupus Erythromatosus. Cells. 2020 Apr;9(4):1049. 16. Petric D. Review of Toxins Associated with Autoimmune Diseases. Sci Prepr [Internet]. 2021 Oct 21 [cited 2024 Nov 3]; Available from: https://www.scienceopen.com/hosted-document?doi=10.14293/S2199-1006.1.SOR-.PPMAW3U.v1 17. Kovacic P, Jacintho JD. Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: unifying theme of oxidative stress. Mini Rev Med Chem. 2003 Sep;3(6):568-75. 18. Mount S. Mount Sinai Health System. [cited 2024 Nov 3]. Systemic lupus erythematosus Information | Mount Sinai - New York. Available from: https://www.mountsinai.org/health-library/report/systemic-lupus-erythematosus 19. Mak A, Tay SH. Environmental Factors, Toxicants and Systemic Lupus Erythematosus. Int J Mol Sci. 2014 Sep;15(9):16043-56. 20. Pan Q, Guo Y, Guo L, Liao S, Zhao C, Wang S, et al. Mechanistic Insights of Chemicals and Drugs as Risk Factors for Systemic Lupus Erythematosus. Curr Med Chem. 27(31):5175-88. 21. Wang Y, Wu H, Li K, Huang R, Liu J, Lu Z, et al. Environmental triggers of autoimmunity: The association between bisphenol analogues and systemic lupus erythematosus. Ecotoxicol Environ Saf. 2024 Jun 15;278:116452. 22. Kharrazian D. Exposure to Environmental Toxins and Autoimmune Conditions. Integr Med Encinitas Calif. 2021 Apr;20(2):20-4. 23. Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016 Sep;28(5):497. 24. Pollard KM, Christy JM, Cauvi DM, Kono DH. Environmental xenobiotic exposure and autoimmunity. Curr Opin Toxicol. 2018 Aug 1;10:15-22. 25. Sarzi-Puttini P, Iaccarino L. Environment and systemic lupus erythematosus: An overview: Autoimmunity: Vol 38 , No 7 - Get Access [Internet]. [cited 2024 Nov 3]. Available from: https://www.tandfonline.com/doi/full/10.1080/08916930500285394 26. Liu JL, Woo JMP, Parks CG, Costenbader KH, Jacobsen S, Bernatsky S. Systemic Lupus Erythematosus Risk: The Role of Environmental Factors. Rheum Dis Clin N Am. 2022 Nov 1;48(4):827-43. 27. Mishra KP, Singh SB. Heavy Metals Exposure and Risk of Autoimmune Diseases: A Review. Arch Immunol Allergy. 2020 Dec 3;3(2):22-6. 28. Bigazzi PE. Autoimmunity and heavy metals. Lupus. 1994 Dec;3(6):449-53. 29. Mishra KP. Lead exposure and its impact on immune system: A review. Toxicol In Vitro. 2009 Sep 1;23(6):969-72. 30. Anka AU, Usman AB. Potential mechanisms of some selected heavy metals in the induction of inflammation and autoimmunity - Abubakar U Anka, Abubakar B Usman, Abubakar N Kaoje, Ramadan M Kabir, Aliyu Bala, Mandana Kazem Arki, Nikoo Hossein-Khannazer, Gholamreza Azizi, 2022 [Internet]. [cited 2024 Nov 3]. Available from: https://journals.sagepub.com/doi/10.1177/1721727X221122719 31. Hemdan NYA, Emmrich F, Faber S, Lehmann J, Sack U. Alterations of Th1/Th2 Reactivity by Heavy Metals. Ann N Y Acad Sci. 2007;1109(1):129-37. 32. Cojocaru M, Chicoş B. The role of heavy metals in autoimmunity. Romanian J Intern Med Rev Roum Med Interne. 2014;52(3):189-91. 33. Caza T, Oaks Z, Perl A. Interplay of Infections, Autoimmunity, and Immunosuppression in Systemic Lupus Erythematosus: International Reviews of Immunology: Vol 33 , No 4 - Get Access. Rev Immunol. 2014 Jan 28;33(4):330-63. 34. Zandman-Goddard G, Shoenfeld Y, Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005 Jan 1;38(7):473-85. 35. Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008 Oct 1;8(1):24-8. 36. Rigante D, Esposito S. Infections and Systemic Lupus Erythematosus: Binding or Sparring Partners? Int J Mol Sci. 2015 Aug;16(8):17331-43. 37. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol. 2002 Apr 1;16(2):281-91. 38. Qiu C, Caricchio R, Gallucci S. Frontiers | Triggers of Autoimmunity: The Role of Bacterial Infections in the Extracellular Exposure of Lupus Nuclear Autoantigens. Front Immunol [Internet]. 2019 Nov 8 [cited 2024 Nov 3];10. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02608/full 39. Marques CPC, Maor Y, de Andrade MS, Rodrigues VP, Benatti BB. Possible evidence of systemic lupus erythematosus and periodontal disease association mediated by Toll-like receptors 2 and 4. Clin Exp Immunol. 2016 Feb 1;183(2):187-92. 40. Pessoa L, Galvão V, Santos-Neto L. Periodontal disease as a risk factor for cardiovascular disease: Suggestion of a further link in systemic lupus erythematosus. Med Hypotheses. 2011 Aug 1;77(2):286-9. 41. Szodoray P, Tarr T, Bazso A, Poor G, Szegedi G, Kiss E. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scand J Rheumatol. 2011 Mar;40(2):122-6. 42. Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. 2011 Sep 1;70(9):1569-74. 43. Cutolo M, Otsa K. Review: Vitamin D, immunity and lupus [Internet]. 2008 [cited 2024 Nov 3]. Available from: https://journals.sagepub.com/doi/10.1177/0961203307085879 44. Abou-Raya S, Helmii M. The Effect of Vitamin D Supplementation on Inflammatory and Hemostatic Markers and Disease Activity in Patients with Systemic Lupus Erythematosus: A Randomized Placebo-controlled Trial. J Rheumatol. 2018 Dec;45(12):1713. 45. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatol Oxf Engl. 2008 Jun;47(6):920-3. 46. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol. 2008 Sep;20(5):532-7. 47. Dall'Ara F, Cutolo M, Andreoli L, Tincani A, Paolino S. Vitamin D and systemic lupus erythematous: a review of immunological and clinical aspects. Clin Exp Rheumatol. 2018;36(1):153-62. 48. Katsuyama T, Moulton VR. Chapter 13 - Hormones. In: Tsokos GC, editor. Systemic Lupus Erythematosus (Second Edition) [Internet]. Academic Press; 2021 [cited 2024 Nov 3]. p. 105-12. Available from: https://www.sciencedirect.com/science/article/pii/B9780128145517000131 49. Moulton VR, Tsokos GC. Why do women get lupus? Clin Immunol. 2012 Jul 1;144(1):53-6. 50. Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum. 2005 Dec;52(12):3701-12. 51. McMurray RW. Sex hormones in the pathogenesis of systemic lupus erythematosus. Front Biosci-Landmark. 2001 Dec 1;6(4):193-206. 52. Crispín JC, Liossis SNC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010 Feb 1;16(2):47-57. 53. Pierdominici M, Ortona E. Estrogen Impact on Autoimmunity Onset and Progression: the Paradigm of Systemic Lupus Erythematosus. In 2013 [cited 2024 Nov 3]. Available from: https://www.semanticscholar.org/paper/Estrogen-Impact-on-Autoimmunity-Onset-and-the-of-Pierdominici-Ortona/e7b114667e74573acb0db515547e993549971f50 54. Cohen-Solal JFG, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex Hormones and SLE: Influencing the Fate of Autoreactive B Cells. In: Radbruch A, Lipsky PE, editors. Current Concepts in Autoimmunity and Chronic Inflammation [Internet]. Berlin, Heidelberg: Springer; 2006 [cited 2024 Nov 3]. p. 67-88. Available from: https://doi.org/10.1007/3-540-29714-6_4 55. Cutolo M, Sulli A, Villaggio B, Seriolo B, Accardo S. Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 1998 Oct 1;57(10):573-7. 56. van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 1994 Sep;37(9):1305-10. 57. Van Vollenhoven RF, Engleman EG, Mcguire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 1995;38(12):1826-31. 58. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8(3):181-7. 59. Crosbie D, Black C, McIntyre L, Royle PL, Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD005114. 60. Caplan T, Caplan B. What Are the Main Triggers and Root Causes of Lupus? [Internet]. 2019. Available from: https://caplanhealthinstitute.com/leaky-gut-main-root-causes-lupus/ 61. Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: Insight into pathogenesis, diagnosis and treatment. World J Gastroenterol WJG. 2010 Jun 28;16(24):2971. 62. Halfon M, Tankeu AT, Ribi C. Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis. Int J Mol Sci. 2024 Jun 3;25(11):6162. 63. García-Carrasco M, Mendoza-Pinto C, Munguía-Realpozo P, Etchegaray-Morales I, Vélez-Pelcastre SK, Méndez-Martínez S, et al. Insulin Resistance and Diabetes Mellitus in Patients with Systemic Lupus Erythematosus. Endocr Metab Immune Disord - Drug Targets. 23(4):503-14. 64. Sánchez-Pérez H, Tejera-Segura B, de Vera-González A, González-Delgado A, Olmos JM, Hernández JL, et al. Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clin Exp Rheumatol. 2017;35(6):885-92. 65. Dawood A, Fayez D, Essa E, El-zorkany K, El-Najjar M, Gazareen S. Study of insulin resistance in patients with systemic lupus erythematosus and rheumatoid arthritis. Menoufia Med J. 2014 Jun 1;27(2):215-25. 66. Koca SS, Karaca I, Yavuzkir MF, Dağli N, Ozgen M, Ustündağ B, et al. Insulin resistance is related with oxidative stress in systemic lupus erythematosus. Anadolu Kardiyol Derg AKD Anatol J Cardiol. 2009 Feb;9(1):23-8. 67. Kawashiri SY, Kawakami A, Fujikawa K, Iwamoto N, Aramaki T, Tamai M, et al. Type B insulin resistance complicated with systemic lupus erythematosus. Intern Med Tokyo Jpn. 2010;49(5):487-90. 68. Alvarez-Payares JC, Ribero D, Rodríguez L, Builes CE, Prieto C, Arango C, et al. Late Systemic Lupus Erythematosus-Associated Insulin Resistance Syndrome: A Rare Cause of De Novo Diabetes Mellitus. Case Rep Med. 2022;2022:4655804. 69. Gehi A, Webb A. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum. 2003 Apr;48(4):1067-70. 70. Knippenberg A, Robinson GA, Wincup C, Ciurtin C, Jury EC, Kalea AZ. Plant-based dietary changes may improve symptoms in patients with systemic lupus erythematosus. Lupus. 2022 Jan 3;31(1):65. 71. Rondanelli M, Patelli Z, Gasparri C, Mansueto F, Ferraris C, Nichetti M, et al. Very low calorie ketogenic diet and common rheumatic disorders: A case report. World J Clin Cases. 2023 Mar 26;11(9):1985. 72. Queen City Health Center. Unlocking the Missing Link for Autoimmune Diseases | Queen City Health Center [Internet]. 2023 [cited 2024 Nov 3]. Available from: 73. Vatsalya V, Li F, Frimodig J, Gala KS, Srivastava S, Kong M, et al. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. Front Pharmacol [Internet]. 2021 Mar 2 [cited 2024 Nov 3];11. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.598128/full 74. Costantini A, Pala MI, Tundo S, Matteucci P. High-dose thiamine improves the symptoms of fibromyalgia. BMJ Case Rep. 2013 May 20;2013:bcr2013009019. 75. Costantini A, Nappo A, Pala MI, Zappone A. High dose thiamine improves fatigue in multiple sclerosis. BMJ Case Rep. 2013 Jul 16;2013:bcr2013009144. 76. MedlinePlus. Thiamine-responsive megaloblastic anemia syndrome: MedlinePlus Genetics [Internet]. [cited 2024 Nov 3]. Available from: https://medlineplus.gov/genetics/condition/thiamine-responsive-megaloblastic-anemia-syndrome/ 77. Mount Sinai. Mount Sinai Health System. [cited 2024 Nov 3]. Vitamin B1 (Thiamine) Information | Mount Sinai - New York. Available from: https://www.mountsinai.org/health-library/supplement/vitamin-b1-thiamine 78. Antonio C. HIGH-D0SE THIAMINE (HDT) THERAPY for Parkinson's Disease. 2024 [cited 2024 Nov 3]. HIGH-D0SE THIAMINE (HDT) THERAPY for Parkinson's Disease. Available from: https://highdosethiamine.org/ 79. Costantini A, Pala MI. Thiamine and Fatigue in Inflammatory Bowel Diseases: An Open-label Pilot Study | The Journal of Alternative and Complementary Medicine [Internet]. [cited 2024 Nov 3]. Available from: https://liebertpub.com/doi/full/10.1089/acm.2011.0840 80. Greco CM, Nakajima C, Manzi S. Updated Review of Complementary and Alternative Medicine Treatments for Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2013 Nov;15(11):378. 81. Ahn H, Lee GS. Riboflavin, vitamin B2, attenuates NLRP3, NLRC4, AIM2, and non-canonical inflammasomes by the inhibition of caspase-1 activity | Scientific Reports [Internet]. [cited 2024 Nov 3]. Available from: https://www.nature.com/articles/s41598-020-76251-7 82. Suwannasom N, Kao I, Pruß A, Georgieva R, Bäumler H. Riboflavin: The Health Benefits of a Forgotten Natural Vitamin. Int J Mol Sci. 2020 Jan 31;21(3):950. 83. Hill LJ, Williams AC. Meat Intake and the Dose of Vitamin B3 - Nicotinamide: Cause of the Causes of Disease Transitions, Health Divides, and Health Futures? Int J Tryptophan Res IJTR. 2017;10:1178646917704662. 84. White SD, Rosychuk RA, Reinke SI, Paradis M. Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs. J Am Vet Med Assoc. 1992 May 15;200(10):1497-500. 85. Surjana D, Damian DL. Nicotinamide in dermatology and photoprotection. Skinmed. 2011;9(6):360-5. 86. Chen AC, Damian DL. Nicotinamide and the skin. Australas J Dermatol. 2014 Aug;55(3):169-75. 87. Gale EA. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab JPEM. 1996;9(3):375-9. 88. Maiese K, Chong ZZ, Hou J, Shang YC. The vitamin nicotinamide: translating nutrition into clinical care. Mol Basel Switz. 2009 Sep 9;14(9):3446-85. 89. Nijhuis L, van de Wetering R. SAT0031 VITAMIN B3 (NAM) SUPPRESSES T CELL ACTIVATION IN AND PRODUCTION OF PRO-INFLAMMATORY CYTOKINES IN VITRO IN A DOSE DEPENDENT MANNER INDICATING THERAPEUTIC POTENTIAL FOR THE TREATMENT OF JIA | Annals of the Rheumatic Diseases [Internet]. [cited 2024 Nov 3]. Available from: https://ard.bmj.com/content/78/Suppl_2/1080.1 90. Rawji KS, Young AMH, Ghosh T, Michaels NJ, Mirzaei R, Kappen J, et al. Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system. Acta Neuropathol (Berl). 2020 May;139(5):893-909. 91. Chen C, Zhang W, Zhou T, Liu Q, Han C, Huang Z, et al. Vitamin B5 rewires Th17 cell metabolism via impeding PKM2 nuclear translocation. Cell Rep. 2022 Nov 29;41(9):111741. 92. Imami M. 3-[(2,4-dihydroxy-3,3-dimethylbutanoyl)amino]propanoic acid (Vitamin B5): Its Synthesis, Transformation into Coenzyme A and Role in Disease. UTSCs J Nat Sci. 2(1):102-15. 93. Minami Y, Hirabayashi Y, Nagata C, Ishii T, Harigae H, Sasaki T. Intakes of vitamin B6 and dietary fiber and clinical course of systemic lupus erythematosus: a prospective study of Japanese female patients. J Epidemiol. 2011;21(4):246-54. 94. Mikkelsen K, Dargahi N, Fraser S, Apostolopoulos V. High-Dose Vitamin B6 (Pyridoxine) Displays Strong Anti-Inflammatory Properties in Lipopolysaccharide-Stimulated Monocytes. Biomedicines. 2023 Sep 19;11(9):2578. 95. Du X, Yang Y, Zhan X, Huang Y, Fu Y, Zhang Z, et al. Vitamin B6 prevents excessive inflammation by reducing accumulation of sphingosine-1-phosphate in a sphingosine-1-phosphate lyase-dependent manner. J Cell Mol Med. 2020 Nov;24(22):13129-38. 96. Cheng CH, Chang SJ, Lee BJ, Lin KL, Huang YC. Vitamin B6 supplementation increases immune responses in critically ill patients. Eur J Clin Nutr. 2006 Oct;60(10):1207-13. 97. Giil LM, Midttun Ø, Refsum H, Ulvik A, Advani R, Smith AD, et al. Kynurenine Pathway Metabolites in Alzheimer's Disease. J Alzheimers Dis JAD. 2017;60(2):495-504. 98. Bendich A, Cohen M. Vitamin B6 safety issues. Ann N Y Acad Sci. 1990;585:321-30. 99. Sedel F, Bernard D, Mock DM, Tourbah A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2016 Nov;110(Pt B):644-53. 100. Isola S, Gammeri L, Furci F, Gangemi S, Pioggia G, Allegra A. Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy. Int J Mol Sci. 2024 Jul 2;25(13):7284. 101. Kodama M, Kodama T, Murakami M, Kodama M. Autoimmune disease and allergy are controlled by vitamin C treatment. Vivo Athens Greece. 1994;8(2):251-7. 102. Tam LS, Li EK, Leung VYF, Griffith JF, Benzie IFF, Lim PL, et al. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol. 2005 Feb;32(2):275-82. 103. Minami Y, Sasaki T, Arai Y, Kurisu Y, Hisamichi S. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol. 2003 Apr;30(4):747-54. 104. Watad A, Neumann SG, Soriano A, Amital H, Shoenfeld Y. Vitamin D and Systemic Lupus Erythematosus: Myth or Reality? Isr Med Assoc J IMAJ. 2016;18(3-4):177-82. 105. Lomarat W, Pakchotanon RR. OP0283 A Randomized Double-Blind Comparative Clinical Trials To Evaluate Efficacy of Vitamin D in Systemic Lupus Erythematosus (SLE) Patients | Annals of the Rheumatic Diseases [Internet]. [cited 2024 Nov 3]. Available from: https://ard.bmj.com/content/75/Suppl_2/165.2 106. Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Anti-vitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci. 2007 Aug;1109:550-7. 107. Lemke D, Klement RJ, Schweiger F, Schweiger B, Spitz J. Vitamin D Resistance as a Possible Cause of Autoimmune Diseases: A Hypothesis Confirmed by a Therapeutic High-Dose Vitamin D Protocol. Front Immunol. 2021;12:655739. 108. Cheng RZ. Understanding and Addressing Vitamin D Resistance: A Comprehensive Approach Integrating Genetic, Environmental, and Nutritional Factors [Internet]. Available from: https://orthomolecular.org/resources/omns/v20n13.shtml 109. Yap KS, Morand EF. Vitamin D and systemic lupus erythematosus: continued evolution. Int J Rheum Dis. 2015 Feb;18(2):242-9. 110. Tolentino M, Cho CC, Lyons JA. Photobiomodulation therapy (PBMT) regulates the production of IL-10 and IFN-Ɣ by peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolated from subjects with Multiple Sclerosis (MS). J Immunol. 2019 May 1;202(1_Supplement):193.16. 111. Tolentino M, Cho CC, Lyons JA. Photobiomodulation (PBM) regulates nitric oxide (NO) production by peripheral blood mononuclear cells (PBMC) isolated from Multiple Sclerosis (MS) patients. J Immunol. 2020 May 1;204(1_Supplement):160.8. 112. Muili KA, Gopalakrishnan S, Meyer SL, Eells JT, Lyons JA. Amelioration of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice by Photobiomodulation Induced by 670 nm Light. PLOS ONE. 2012 Jan 24;7(1):e30655. 113. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A Pilot study - Knobler - 1992 - Arthritis & Rheumatism - Wiley Online Library [Internet]. [cited 2024 Nov 3]. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.1780350311 114. Motta S, Monti M. Photodynamic therapy-a promising treatment option for autoimmune skin ulcers: a case report | Photochemical & Photobiological Sciences [Internet]. Nov. 1, 27 [cited 2024 Nov 3]. Available from: https://link.springer.com/article/10.1039/b711920h 115. Wang J, Zhao C, Kong P, Bian G, Sun Z, Sun Y, et al. Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response. J Neuroimmunol. 2016 Oct 15;299:45-52. 116. Yin Y, Choi SC. Normalization of CD4+ T cell metabolism reverses lupus | Science Translational Medicine [Internet]. 2015 [cited 2024 Nov 3]. Available from: https://www.science.org/doi/10.1126/scitranslmed.aaa0835 117. Singer DS, Kohn LD, Zinger H, Mozes E. Methimazole prevents induction of experimental systemic lupus erythematosus in mice. J Immunol. 1994 Jul 15;153(2):873-80. 118. Reilly CM, Regna N, Mishra N. HDAC Inhibition in Lupus Models. Mol Med. 2011 May;17(5):417-25. 119. Weeding E, Sawalha AH. Deoxyribonucleic Acid Methylation in Systemic Lupus Erythematosus: Implications for Future Clinical Practice. Front Immunol [Internet]. 2018 Apr 24 [cited 2024 Nov 3];9. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00875/full 120. Albano S, Gallicchio VS. Systemic Lupus Erythematosus & Stem Cell Therapy. Stem Cell Regen Med [Internet]. 2023 Jun 30 [cited 2024 Nov 3];7(1). Available from: https://www.scivisionpub.com/pdfs/systemic-lupus-erythematosus--stem-cell-therapy-2774.pdf 121. Li A, Guo F, Pan Q, Chen S, Chen J, Liu H feng, et al. Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus. Front Immunol [Internet]. 2021 Sep 30 [cited 2024 Nov 3];12. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.728190/full 122. Yang Q, Liu Y. An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus - Yang - 2021 - Stem Cells International - Wiley Online Library [Internet]. 2021 [cited 2024 Nov 3]. Available from: https://onlinelibrary.wiley.com/doi/10.1155/2021/2168595 123. Zare Moghaddam M, Mousavi MJ, Ghotloo S. Stem cell-based therapy for systemic lupus erythematous. J Transl Autoimmun. 2024 Jun 1;8:100241. 124. Yuan X, Sun L. Stem cell therapy in lupus. Rheumatol Immunol Res. 2022 Jun 1;3(2):61-8. 125. Sui W, Hou X, Che W, Chen J, Ou M, Xue W, et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin Immunol. 2013 Aug 1;148(2):186-97. 126. Cheng RZ. Integrative Low Carb/Orthomolecular Medicine for Autoimmune Diseases [Internet]. 2022 Sep 5. Available from: https://www.youtube.com/watch?v=noScK80HVMs 127. Cheng RZ. Reversing Hashimoto's Thyroiditis with Orthomolecuar Medicine [Internet]. 2022. Available from: https://www.drwlc.com/blog/2022/05/20/reversing-hashimotos-thyroiditis-with-orthomolecular-medicine/ Nutritional Medicine is Orthomolecular MedicineOrthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org Find a DoctorTo locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource. Editorial Review Board:
Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication. To Subscribe at no charge: http://www.orthomolecular.org/subscribe.html To Unsubscribe from this list: http://www.orthomolecular.org/unsubscribe.html |
This website is managed by Riordan Clinic
A Non-profit 501(c)(3) Medical, Research and Educational Organization
3100 North Hillside Avenue, Wichita, KS 67219 USA
Phone: 316-682-3100; Fax: 316-682-5054
© (Riordan Clinic) 2004 - 2024c
Information on Orthomolecular.org is provided for educational purposes only. It is not intended as medical advice.
Consult your orthomolecular health care professional for individual guidance on specific health problems.